Generic captions
이번 3상 연구에서 무진행생존기간 중앙값은 28.5개월이었습니다.
In this trial, the median survival without progression was 28.5 months.
Paraphrases 'progression-free survival' into everyday words, so it isn't the standard clinical metric
All use cases
Conferences and symposia where a single term or number is trust itself
A multidisciplinary conference where terms like targeted therapy, biomarkers, OS, and PFS come nonstop. One wrong term chips away at the conference's credibility. barotalk enforces standard spellings with its built-in medical glossary, so captions are accurate from the very first line — overseas speakers' talks flow in Korean, and domestic talks in English, at the same time.
99.2%
Clinical term accuracy
12개
Languages broadcast at once
~1초
Caption latency
120+
Built-in medical terms
실시간 송출 · LED + 관객 폰1.0s
원문 · 한국어
이번 3상 연구에서 무진행생존기간(PFS) 중앙값은 28.5개월, 위험비는 0.72였습니다.
English
In this phase 3 trial, median progression-free survival (PFS) was 28.5 months, with a hazard ratio of 0.72.
日本語
本第3相試験では、無増悪生存期間（PFS）中央値は28.5か月、ハザード比は0.72でした。
한 발화가 LED 스크린과 모든 참석자 폰에 각자 언어로 동시에 떠요.
One term can make or break trust
Generic interpretation paraphrases; barotalk carries standard metrics through exactly, using its built-in glossary.
barotalk's term-aware captions
이번 3상 연구에서 무진행생존기간 중앙값은 28.5개월이었습니다.
In this phase 3 trial, median progression-free survival (PFS) was 28.5 months.
Uses the built-in medical glossary to carry it through as the standard metric 'progression-free survival (PFS)'
내장 의학 용어집
127개
의학 용어가 이미 들어 있어요
별도 등록 없이 표준 표기로 번역돼요. 행사 자료를 올리면 빠진 용어까지 자동으로 채워져요.
종양학25
표적치료targeted therapy면역항암제immunotherapy면역관문억제제immune checkpoint inhibitor항암화학요법chemotherapy방사선치료radiation therapy전이metastasis종양tumor악성malignant양성benign생검biopsy병기staging관해remission재발recurrence고형암solid tumor혈액암hematologic cancer림프종lymphoma백혈병leukemia삼중음성 유방암triple-negative breast cancer (TNBC)종양표지자tumor markerHER2 양성HER2-positivePD-L1 발현PD-L1 expression종양미세환경tumor microenvironment선행항암요법neoadjuvant therapy보조요법adjuvant therapy완화의료palliative care
임상시험17
임상시험clinical trial3상 임상시험phase 3 trial무작위배정randomization이중맹검double-blind위약placebo1차 평가변수primary endpoint전체생존기간(OS)overall survival (OS)무진행생존기간(PFS)progression-free survival (PFS)객관적반응률(ORR)objective response rate (ORR)무병생존기간(DFS)disease-free survival (DFS)위험비(HR)hazard ratio (HR)신뢰구간(CI)confidence interval (CI)배정대로분석(ITT)intention-to-treat (ITT)적응증indicationNCCN 가이드라인NCCN GuidelinesESMO 가이드라인ESMO Guidelines실사용근거(RWE)real-world evidence (RWE)
제약·바이오12
바이오시밀러biosimilar단클론항체monoclonal antibody (mAb)항체-약물 접합체(ADC)antibody-drug conjugate (ADC)백신vaccine엠알엔에이(mRNA)mRNA약물동태pharmacokinetics (PK)약력학pharmacodynamics (PD)이상반응adverse event내성resistance병용요법combination therapy생체이용률bioavailability반감기half-life
순환기9
고혈압hypertension심부전heart failure심근경색myocardial infarction심방세동atrial fibrillation부정맥arrhythmia관상동맥질환coronary artery disease박출률ejection fraction콜레스테롤cholesterol동맥경화atherosclerosis
신경7
뇌졸중stroke뇌전증epilepsy파킨슨병Parkinson's disease알츠하이머병Alzheimer's disease다발성경화증multiple sclerosis신경퇴행neurodegeneration인지장애cognitive impairment
내분비·대사6
당뇨병diabetes mellitus인슐린 저항성insulin resistance갑상선thyroid비만obesity대사증후군metabolic syndrome당화혈색소(HbA1c)HbA1c
감염6
항생제antibiotics항바이러스제antiviral패혈증sepsis항생제 내성antimicrobial resistance (AMR)병원체pathogen잠복기incubation period
소화기·호흡기6
내시경endoscopy간경변cirrhosis염증성 장질환inflammatory bowel disease (IBD)만성폐쇄성폐질환(COPD)COPD폐렴pneumonia폐섬유증pulmonary fibrosis
신장·비뇨4
만성콩팥병chronic kidney disease (CKD)투석dialysis사구체여과율(GFR)glomerular filtration rate (GFR)단백뇨proteinuria
영상·진단검사7
자기공명영상(MRI)MRI컴퓨터단층촬영(CT)CT scan양전자방출단층촬영(PET)PET scan초음파ultrasound조직병리histopathology면역조직화학(IHC)immunohistochemistry (IHC)액체생검liquid biopsy
정밀·첨단11
정밀의료precision medicine유전자치료gene therapy세포치료cell therapy카티치료CAR-T cell therapy바이오마커biomarker차세대염기서열분석(NGS)next-generation sequencing (NGS)크리스퍼(CRISPR)CRISPR오가노이드organoid디지털치료제digital therapeutics (DTx)원격의료telemedicineAI 보조 진단AI-assisted diagnosis
규제·인허가8
식약처Ministry of Food and Drug Safety (MFDS)FDA 승인FDA approval혁신치료제 지정breakthrough therapy designation희귀의약품orphan drug사전동의informed consent임상시험심사위원회(IRB)Institutional Review Board (IRB)임상시험관리기준(GCP)good clinical practice (GCP)의료기술평가(HTA)health technology assessment (HTA)
일반9
예후prognosis진단diagnosis동반질환comorbidity합병증complication병인etiology발병기전pathogenesis발생률incidence유병률prevalence삶의 질(QoL)quality of life (QoL)
From setup to wrap-up
01
Setup
- Upload presentation materials → drugs, biomarkers, and clinical endpoints extracted automatically
- Lock the standard glossary (표적치료 → targeted therapy)
- Split term sets by session for higher accuracy
- Lock speaker names and drug brand names as proper nouns
02
During the event
- 0-second term substitution keeps captions accurate from the very first line
- Numbers and units cleaned up automatically (HR 0.72, OS 28.5 months)
- Add a short note for terms that are easy to confuse
- Q&A and panel discussion captioned too
03
After the event
- A per-session, per-speaker replay archive
- Full transcripts cut abstract and review time
- Frequently used terms suggested automatically for your next conference
Need a setup like this event?
Sign up and we'll have the same setup running for you in under 30 minutes.
Create your event free